1. China Stocks

  2. •

    Distribution services

  3. •

    Medical distributors
Shanghai Haohai Biological Technology Co., Ltd. Class A

Shanghai Haohai Biological Technology Co., Ltd. Class A

1.80
EUR
+0.01
(+0.56%)
791.46MMarket Cap
Oct 23Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.38
1.52
1.79
2.83
3.26
3.3
2.52
3.35
4.08
5.21
5.42
4.98
- -
Basic EPS, GAAP
0.49
0.63
0.64
0.78
0.87
0.77
0.44
0.67
0.35
0.82
0.85
0.51
- -
Free Cash Flow per Basic Share
0.13
0.45
0.38
0.44
0.5
-0.1
0.13
0.13
-0.17
0.73
0.58
0.62
- -
Dividend per Share
0.19
0.11
0.12
0.18
0.17
0.17
0.24
0.17
0.24
0.14
0.53
0.47
- -
Book Value per Share
1.59
7.13
7.78
8.58
9.68
10.34
10.41
10.95
10.67
11.11
11.41
11.31
11.12
Tangible Book Value per Share
1.5
7.04
6.13
6.37
7.54
8.54
8.58
8.67
8.36
8.86
9.1
9.62
9.79
Basic Weighted Avg Shares
373
436
475
475
475
484
526
523
515
506
494
491
356
Sales/Revenue/Turnover
516
664
851
1,345
1,546
1,595
1,324
1,750
2,103
2,635
2,680
2,446
- -
Operating Margin (%)
41.31
38.06
36.43
30.9
24.5
21.85
9.46
13
10.47
16.64
16.65
12.96
- -
Depreciation Expense
23
34
36
68
84
115
133
163
204
198
205
207
- -
Net Income, GAAP
184
273
305
372
415
371
230
352
180
416
420
251
- -
Effective Tax Rate (%)
14.86
14.76
15.1
13.35
13.35
13.35
11.94
9.24
19.26
18.89
19.29
12.93
- -
Profit Margin (%)
35.58
41.19
35.84
27.69
26.82
23.24
17.37
20.13
8.58
15.79
15.69
10.26
- -
Working Capital
208
2,231
1,952
1,908
1,843
3,585
3,376
3,225
3,021
3,034
2,792
2,548
2,387
LT Debt
- -
- -
- -
18
16
24
20
39
84
191
143
64
18
Total Equity
594
2,665
2,986
3,385
3,835
5,653
5,734
6,060
5,902
6,017
5,917
5,605
5,458
Return on Invested Capital (%)
- -
16.48
10.96
10.8
8.87
6.31
1.93
3.49
2.71
5.73
5.65
4.46
- -
Return on Capital (%)
- -
16.79
10.56
10.78
10.3
7.71
4.12
6.02
2.9
6.84
7.49
5.01
- -
Return on Common Equity (%)
- -
16.8
10.96
12.2
12.17
8.18
4.2
6.29
3.21
7.45
7.49
4.57
- -

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
335
- -
425
LT Borrowings
33
- -
- -
LT Finance Leases
31
- -
18
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
479
35
477
Market Capitalization
10,399
- -
6,135

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
3,463
- -
3,345
Cash, Cash Equivalents & STI
2,522
- -
2,394
Accounts Receivable, Net
271
- -
267
Inventories
523
- -
522
Total Current Liabilities
915
- -
958
Payables & Accruals
- -
- -
- -
ST Debt
335
- -
425
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.56%
-0.38%
-5.28%
Free Cash Flow
-109.07%
-151.96%
6.65%
Net Income, GAAP
9.21%
19.13%
-40.3%
Sales/Revenue/Turnover
15.79%
14.12%
-8.71%
Total Cash Common Dividend
- -
46.6%
-11.98%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
646
758
- -
- -
2,680
2025
- -
- -
- -
- -
2,446
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.19
0.59
- -
- -
0.85
2025
- -
- -
- -
- -
0.51
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.53
2025
- -
- -
- -
- -
0.47
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Jian Ying Wu
Full Time Employees
2,110
Sector
Distribution services
Industry
Medical distributors
Address
WenGuang Plaza Shanghai SH China 200336
IPO Date
Apr 30, 2015
Website
3healthcare.com
Similar Companies
DataMeds AI, Inc. (NASDAQ:MEDS)
Selcuk Ecza Deposu Ticaret ve Sanayi A.S. (BIST:SELEC)
McKesson Corporation (NYSE:MCK)
Ibnsina Pharma (EGX:ISPH)
Cardinal Health, Inc. (NYSE:CAH)
Entero Healthcare Solutions Limited (NSE:ENTERO)
Business
Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials and biological products. Its main product portfolio includes ophthalmology products such as intraocular lenses, medical sodium hyaluronate gel, and lubricant eye drops; orthopedics products including sodium hyaluronate injection, medical chitosan, and medical sodium hyaluronate gel; medical aesthetics and wound care products featuring recombinant human epidermal growth factor and hyaluronic acid-based dermal fillers and gels; as well as anti-adhesion and hemostasis products like medical collagen sponges. The company also provides biological reagents, instruments, and related technology transfer and consultation services. Founded in 2007 and headquartered in Shanghai, China, Shanghai Haohai Biological Technology operates primarily in Mainland China with emerging global reach including Europe and the United States. Recent major developments include the successful approval in July 2024 of "Haimi Yuebai," the first globally organic cross-linked high-end hyaluronic acid product characterized by precise sculpting capabilities, marking an advancement into the high-end medical aesthetics market. The company has also expanded its medical aesthetics business through key acquisitions and investments, such as the acquisition of a full stake in a lens manufacturing unit in 2024, bolstering its ophthalmology product line. Additionally, it maintains strategic partnerships with academic institutions and distributors, enhancing R&D and market penetration. Shanghai Haohai continues to focus on innovation in bioengineering, ophthalmology, medical aesthetics, and orthopedics while navigating industry regulatory compliance and expanding its international footprint.